2021-2030 Analysis and Review Polyene Phosphatidylcholine Market
Polyene Phosphatidylcholine Market by Clinical Application (Liver Diseases, Dietary Supplements, and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The polyene phosphatidylcholine market was valued at USD 265.7 Mn by 2019. The rising prevalence of hepatic disorders worldwide primarily drives market growth. Additionally, the growing significance of polyene phosphatidylcholine as a dietary supplement will further propel the market growth in the near future.
Polyene phosphatidylcholine is an unsaturated version of phosphatidylcholine which is derived from natural sources such as soybeans, eggs, sunflowers, mustard, etc. it occurs naturally in the human cells. It is widely employed for its therapeutic efficacy against hepatic disorders, ulcerative colitis, cognitive functions, etc. commercially available as injectable and capsules. Technological advancement in nutrition science has increased the demand for dietary supplements enriched in polyene phosphatidylcholine.
The major segments related to the polyene phosphatidylcholine market are:
By Clinical Application (2017–2027; US$ Mn)
Liver Diseases
Dietary Supplements
Others
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment (2017–2027; US$ Mn)
North America
U.S.
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning.
Significant customers?
Segment Analysis
Liver diseases are spearheading the clinical application segment for the polyene phosphatidylcholine market. According to the latest statistics provided by the World Health Organization (WHO), approximately 2 million people die due to liver diseases each year across the globe. The various types of liver diseases frequently encountered in human beings are Hepatitis, A, B, C, liver cirrhosis, fatty liver disease, hemochromatosis, etc. The early clinical manifestations associated with liver diseases are yellowish eyes and skin, dark urine, pale stool color, swelling of legs and ankles, etc. Dietary supplements are gaining immense popularity since the last 2 decades on account of its lipotropic activity which prevents the excess lipid migration from the liver to blood vessels thereby preventing the occurrence of cardiovascular complications. Additionally, clinical studies have reported that polyene phosphatidylcholine is vital in liver repair, facilitates dissolving of gallstones, and eases the pain associated with ulcerative colitis.
Hospital pharmacy is presently the supreme leader in the distribution channel segment for the polyene phosphatidylcholine market. The drug is associated with severe side effects such as pain, itching, edema, at the site of injection and diarrhea, and nausea for oral formulations, hence it is mandatory for the precise dispensing of medications under the supervision of hospital pharmacist. Retail pharmacy is expected to register significant market growth in the near future on account of access to government-subsidized essential medications in the developing regions.
North America is presently leading the geography segment for the polyene phosphatidylcholine market. The rising prevalence of hepatic disorders primarily drives market growth in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately 4.5 million people in the United States are diagnosed with liver disease. Developed healthcare infrastructure and affordable reimbursement scenarios further drive the market growth in the region. Europe is the second-largest regional market in the regional segment for the polyene phosphatidylcholine market. The supportive regulatory environment provides by the European Medical Agency for the manufacturing of polyene phosphatidylcholine drug formulations drives the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the polyene phosphatidylcholine market. Developing healthcare infrastructure and flourishing generic drug formulations market together provide a positive thrust to the market growth in the Asia Pacific region.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |